EE46 An Early Cost-Effectiveness Analysis of Abelacimab Versus Rivaroxaban, a Standard of Care Direct Oral Anticoagulant (DOAC), in Patients with Atrial Fibrillation Using Preliminary Results from the AZALEA-TIMI 71 Trial
Jun 1, 2024, 00:00 AM
10.1016/j.jval.2024.03.347
https://www.valueinhealthjournal.com/article/S1098-3015(24)00462-5/fulltext
Section Title :
Section Order :
11693
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)00462-5&doi=10.1016/j.jval.2024.03.347